Pfizer (PFE) remains in focus for income oriented investors, with recent returns ranging from a 2.1% decline over the past week to a 10.7% total return over the past year. See our latest analysis for ...

If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the ...

Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is drawing attention after recent trading left the shares at a ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Pfizer (NYSE:PFE) has agreed to acquire Metsera (NASDAQ:MTSR) in a deal worth $47.50 per share in cash, valuing the company at $4.9 billion upfront, with the potential for shareholders to receive up ...

Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...

Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...